ArticleJournal of feline medicine and surgery2026
Antibody responses to inactivated (adjuvanted) and attenuated (non-adjuvanted) feline panleukopaenia virus vaccination, including in different injection sites.
Article in Journal of feline medicine and surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
ObjectivesVaccines have traditionally been administered to cats into the interscapular subcutaneous region ('scruff') for ease of restraining the cat while the vaccine is injected. Concern about feline injection-site sarcomas (FISSs) has prompted recommendations to use distal sites such as the hindlimb or tail, but evidence of adequate immune response at these sites is limited. This field study evaluated the antibody response to feline panleukopaenia virus (FPV) in kittens vaccinated with one of two commercial vaccines, injected at different sites.MethodsAn inactivated (killed), adjuvanted pentavalent vaccine (Fel-O-Vax 5; Boehringer Ingelheim Animal Health Australia) was injected subcutaneously into the scruff, left distal hindlimb or proximal tail. A modified-live virus (attenuated [MLV]), non-adjuvanted trivalent vaccine (Feligen RCP; Virbac Animal Health Australia) was given into the scruff only. For the latter, an inactivated, adjuvanted monovalent feline leukaemia virus vaccine was administered concurrently into the contralateral scruff, left distal hindlimb or proximal tail. Only one FPV-containing vaccine was administered to each cat/kitten: either the inactivated vaccine given in one of the three different anatomical regions or the MLV vaccine given into the scruff only. Cats were re-vaccinated in the same site and using the same vaccine type. Kittens were randomly allocated into study groups according to order of recruitment. Kittens were sampled at four time points over 12 months (T0, T1, T2 and T12). Protective FPV antibody titres were determined by haemagglutination inhibition (HI; negative <1:32, positive ⩾1:32).ResultsSamples from 100 kittens (T0, T1, T2) and 77 returning adult cats (T12) were available for FPV antibody testing (median age of kittens at T0 was 13 weeks, range 7-16). Eight kittens (8%) were found to be HI-positive at T0. Protective titres did not differ significantly among the three injection sites for the inactivated vaccine. Linear modelling demonstrated that antibody titres were higher in kittens given the MLV vaccine compared with kittens given the inactivated vaccine at T1 (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.